The trial includes dose escalation and dose expansion and optimization phases. The study is currently enrolling in dose escalation. "B7-H4 represents an attractive target for ADC therapy given its ...

LNCB74 is undergoing a Phase 1 study, highlighting NextCure's commitment to developing novel cancer therapies. The presentation of trial results at ASCO emphasizes the significance and visibility of ...

Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose ...

Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior ...

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization The study is currently enrolling ...